Graham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Graham Capital Management L.P. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 37,577 shares of the biopharmaceutical company's stock, valued at approximately $321,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix during the fourth quarter worth approximately $43,000. AlphaQuest LLC acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $53,000. Tower Research Capital LLC TRC increased its holdings in shares of Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 8,446 shares during the last quarter. Walleye Capital LLC bought a new stake in Ocular Therapeutix in the 4th quarter valued at $90,000. Finally, XTX Topco Ltd acquired a new stake in Ocular Therapeutix during the 4th quarter valued at $99,000. 59.21% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of the company's stock in a transaction dated Thursday, May 8th. The stock was purchased at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their position. The disclosure for this purchase can be found here. 2.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on OCUL. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 target price for the company. William Blair started coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC dropped their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.25.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $7.22 on Friday. The stock's fifty day moving average price is $7.41 and its two-hundred day moving average price is $8.13. The firm has a market cap of $1.15 billion, a PE ratio of -5.47 and a beta of 1.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a one year low of $4.79 and a one year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. As a group, research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.